STT3B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25725788	1.00	1/20
SCHEMBL25726108	1.00	1/20
SCHEMBL25726112	1.00	1/20
SCHEMBL25726328	0.85	1/20
SCHEMBL25733879	0.85	1/20
SCHEMBL25726322	0.82	1/20
SCHEMBL25726324	0.82	1/20
SCHEMBL25725970	0.78	1/20
SCHEMBL25726199	0.78	1/20
SCHEMBL25726040	0.74	1/20
SCHEMBL25733881	0.74	1/20
SCHEMBL25733944	0.73	1/20
SCHEMBL25726323	0.73	1/20
SCHEMBL25726233	0.72	1/20
SCHEMBL25726277	0.72	1/20
SCHEMBL25725787	0.72	1/20
SCHEMBL25726116	0.72	1/20
SCHEMBL25726119	0.72	1/20
SCHEMBL25733932	0.72	1/20
SCHEMBL25726372	0.71	1/20

Clinical trials — most relevant to STT3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
GD2/CD70 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
GD2/CD56 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects	nan	UNKNOWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Biomarker for Hurler Disease (BioHurler)	nan	WITHDRAWN
Canadian Fabry Disease Initiative (CFDI) National Registry	nan	RECRUITING
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta	nan	RECRUITING
Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer	nan	RECRUITING
Dietary Monosaccharide Supplementation in Patients With Congenital Disorders of Glycosylation	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
The Natural History of Sialidosis Type I	nan	RECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a STT3B binder may also engage these)

Protein	Name	Similarity
Q3TDQ1	—	1.000	Q3TDQ1 →
E2RG47	—	0.999	E2RG47 →
Q7XQ88	—	0.997	Q7XQ88 →
O94335	—	0.995	O94335 →
Q6F2Z1	—	0.994	Q6F2Z1 →
Q5RCE2	—	0.993	Q5RCE2 →
STT3A	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A	0.993	landscape →
P39007	—	0.993	P39007 →
F1PJP5	—	0.993	F1PJP5 →
Q93ZY3	—	0.993	Q93ZY3 →
Q2KJI2	—	0.992	Q2KJI2 →
A8Y3M2	—	0.992	A8Y3M2 →
P46978	—	0.992	P46978 →
Q7Z388	—	0.990	Q7Z388 →
O97681	—	0.989	O97681 →
D4AD75	—	0.989	D4AD75 →
Q9HDZ2	—	0.989	Q9HDZ2 →
P25618	—	0.988	P25618 →
P34413	—	0.988	P34413 →
Q29IL2	—	0.988	Q29IL2 →
P12683	—	0.988	P12683 →
O93869	—	0.988	O93869 →
P23337	—	0.987	P23337 →
Q93380	—	0.987	Q93380 →
Q54E04	—	0.987	Q54E04 →
P0CW70	—	0.987	P0CW70 →
Q9Z1E4	—	0.987	Q9Z1E4 →
P46975	—	0.987	P46975 →
Q9UTI7	—	0.987	Q9UTI7 →
D4A2Z8	—	0.987	D4A2Z8 →